# Louisiana Medicaid Apomorphine (Onapgo™)

The *Louisiana Uniform Prescription Drug Prior Authorization Form* should be utilized to request clinical authorization for apomorphine (Onapgo<sup>TM</sup>).

Additional Point-of-Sale edits may apply.

By submitting the authorization request, the prescriber attests to the conditions available <u>HERE</u>.

### **Approval Criteria for Initiation of Therapy**

- The recipient has a diagnosis of advanced Parkinson's disease; AND
- This medication is prescribed by, or the request states that the medication is being prescribed in consultation with, a neurologist; **AND**
- The prescriber **states on the request** that the recipient has motor fluctuations even with compliant use of optimized pharmacotherapy for advanced Parkinson's disease.

## **Approval Criteria for Continuation of Therapy**

• The prescriber **states on the request** that the recipient is established on the medication with evidence of a positive response to therapy.

### Duration of approval for initiation and continuation of therapy: 12 months

### Reference

Onapgo (apomorphine) [package insert]. Rockville, MD: MDD US Operations, LLC; February 2025. https://www.onapgo.com/onapgo\_PI.pdf

Revision / Date	Implementation Date
Policy created / February 2025	August 2025